{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:32:07Z","timestamp":1794508327855,"version":"4.9.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100006342","name":"Association Vaincre la Mucoviscidose","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondation Sauver la Vie"},{"name":"Fili\u00e8re MUCO CFTR"},{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise de la Mucoviscidose"},{"DOI":"10.13039\/501100006342","name":"Association Vaincre la Mucoviscidose","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondation Sauver la Vie"},{"name":"Fili\u00e8re MUCO CFTR"},{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise de la Mucoviscidose"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Limited data exist on the safety and effectiveness of elexacaftor-tezacaftor-ivacaftor (ETI) in people with cystic fibrosis (pwCF) and advanced lung disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the effects of ETI in an unselected population of pwCF and advanced lung disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective observational study, including all adults aged 18\u2009years and older with percentage predicted forced expiratory volume in 1\u2009second (ppFEV1)\u2009\u2a7d\u200940 who initiated ETI from December 2019 to June 2021 in France, was conducted. PwCF were followed until August 8, 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ETI was initiated in 434 pwCF with a median ppFEV1 of 30 (interquartile range, 25\u201335), including 27 with severe cystic fibrosis liver disease and 183 with diabetes. PwCF were followed for a median of 587 (interquartile range, 396\u2013728) days after ETI initiation. Discontinuation of ETI occurred in 12 (2.8%) pwCF and was due mostly to lung transplantation (n\u2009=\u20095) or death (n\u2009=\u20094). Absolute increase in ppFEV1 by a mean of +14.2% (95% confidence interval, 13.1\u201315.4%) occurred at 1 month and persisted throughout the study. Increase in ppFEV1 in the youngest age quartile was almost twice that of the oldest quartile (P\u2009&amp;lt;\u20090.001); body mass index\u2009&amp;lt;\u200918.5\u2009kg\/m2 was found in 38.6% at initiation versus 11.3% at 12 months (P\u2009=\u20090.0001). Increases in serum concentrations of vitamins A and E, but not 25-hydroxy vitamin D3, were observed. Significant reductions in the percentages of pwCF using oxygen therapy, noninvasive ventilation, nutritional support, and inhaled and systemic therapies (including antibiotics) were observed; insulin was discontinued in 12% of patients with diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ETI is safe in pwCF and advanced lung disease, with multisystem pulmonary and extrapulmonary benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202312-1065oc","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T15:24:25Z","timestamp":1712330665000},"page":"1053-1064","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":47,"title":["Multisystemic Effects of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease"],"prefix":"10.1093","volume":"21","author":[{"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Institut Cochin, INSERM U1016, Paris, France"},{"name":"Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"ERN-Lung CF Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Paillasseur","sequence":"additional","affiliation":[{"name":"Effi-Stat, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durieu","sequence":"additional","affiliation":[{"name":"Centre de R\u00e9f\u00e9rence Adulte de la Mucoviscidose, Service de M\u00e9decine Interne, Hospices Civils de Lyon, Pierre B\u00e9nite, France"},{"name":"University of Lyon, Laboratoire de recherche en sant\u00e9 publique RESHAPE, INSERM U1290, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Reynaud-Gaubert","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Lung Transplantation, Adult Cystic Fibrosis Center Aix Marseille University, Assistance Publique\u2013H\u00f4pitaux de Marseille, H\u00f4pital Nord, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hamidfar","sequence":"additional","affiliation":[{"name":"Service Hospitalo-Universitaire de Pneumologie et Physiologie, P\u00f4le Thorax et Vaisseaux, Centre Hospitalier Universitaire de Grenoble-Alpes, La Tronche, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marl\u00e8ne","family":"Murris-Espin","sequence":"additional","affiliation":[{"name":"Centre de Ressources et de Comp\u00e9tences de la Mucoviscidose, Service de Pneumologie P\u00f4le des Voies Respiratoires, H\u00f4pital Larrey CHU de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Danner-Boucher","sequence":"additional","affiliation":[{"name":"Service de Pneumologie, L\u2019Institut du Thorax, CHU Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Chiron","sequence":"additional","affiliation":[{"name":"Centre de Ressources et de Comp\u00e9tences de la Mucoviscidose, H\u00f4pital Arnaud de Villeneuve, Centre Hospitalier Universitaire de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Leroy","sequence":"additional","affiliation":[{"name":"Service de Pneumologie, Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, F\u00e9d\u00e9ration Hospitalo-Universitaire OncoAge, Centre National de la Recherche Scientifique, INSERM, Institute for Research on Cancer and Ageing Nice Team 3, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Douvry","sequence":"additional","affiliation":[{"name":"Service de Pneumologie, Centre Hospitalier Intercommunal, FHU SENEC, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Grenet","sequence":"additional","affiliation":[{"name":"Centre de Ressources et Comp\u00e9tences de la Mucoviscidose, Centre de Transplantation Pulmonaire, Service de Pneumologie, H\u00f4pital Foch, Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mely","sequence":"additional","affiliation":[{"name":"H\u00f4pital Ren\u00e9e Sabran, Centre de Ressources et de Comp\u00e9tences de la Mucoviscidose, Giens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ramel","sequence":"additional","affiliation":[{"name":"Centre de Ressources et de Comp\u00e9tences de la Mucoviscidose, Fondation Ildys, Roscoff, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Montcouquiol","sequence":"additional","affiliation":[{"name":"CHU Clermont-Ferrand, Centre de Ressources et de Comp\u00e9tences de la Mucoviscidose, Clermont-Ferrand, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esp\u00e9rie","family":"Burnet","sequence":"additional","affiliation":[{"name":"Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"ERN-Lung CF Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El Hassane","family":"Ouaalaya","sequence":"additional","affiliation":[{"name":"Effi-Stat, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Sogni","sequence":"additional","affiliation":[{"name":"Liver Unit, Cochin Hospital and Paris Cit\u00e9 University, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Da Silva","sequence":"additional","affiliation":[{"name":"Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"ERN-Lung CF Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Martin","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Institut Cochin, INSERM U1016, Paris, France"},{"name":"Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"ERN-Lung CF Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"2026012203161223000_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012203161223000_bib2","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"2026012203161223000_bib3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203161223000_bib4","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2026012203161223000_bib5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012203161223000_bib6","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012203161223000_bib7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203161223000_bib8","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/ppul.26318","article-title":"Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis","volume":"58","author":"McCoy","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026012203161223000_bib9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jcf.2022.06.003","article-title":"Elexacaftor-tezacaftor-ivacaftor improve gastro-oesophageal reflux and sinonasal symptoms in advanced cystic fibrosis","volume":"21","author":"Shakir","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026012203161223000_bib10","doi-asserted-by":"crossref","first-page":"106646","DOI":"10.1016\/j.rmed.2021.106646","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del\/minimal function genotype","volume":"189","author":"Carnovale","year":"2021","journal-title":"Respir Med"},{"key":"2026012203161223000_bib11","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1513\/AnnalsATS.202102-220RL","article-title":"Efficacy of elexacaftor\/tezacaftor\/ivacaftor in advanced cystic fibrosis lung disease","volume":"18","author":"Djavid","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203161223000_bib12","doi-asserted-by":"crossref","first-page":"2003079","DOI":"10.1183\/13993003.03079-2020","article-title":"Efficacy of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease","volume":"57","author":"O\u2019Shea","year":"2021","journal-title":"Eur Respir J"},{"key":"2026012203161223000_bib13","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/jcm11041021","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation and advanced lung disease: a 48-week observational study","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"2026012203161223000_bib14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203161223000_bib15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcf.2022.01.012","article-title":"Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis","volume":"21","author":"Martin","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026012203161223000_bib16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jcf.2020.02.015","article-title":"Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease","volume":"19","author":"Kapnadak","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026012203161223000_bib17","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(11)60006-4","article-title":"Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease","volume":"10","author":"Debray","year":"2011","journal-title":"J Cyst Fibros"},{"key":"2026012203161223000_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"2026012203161223000_bib19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of lumacaftor-ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203161223000_bib20","doi-asserted-by":"crossref","first-page":"e122695","DOI":"10.1172\/jci.insight.122695","article-title":"Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR","volume":"3","author":"Donaldson","year":"2018","journal-title":"JCI Insight"},{"key":"2026012203161223000_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01344-2021","article-title":"Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis","author":"Campredon","year":"2021","journal-title":"Eur Respir J"},{"key":"2026012203161223000_bib22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1164\/rccm.201507-1281OC","article-title":"Morphometric analysis of explant lungs in cystic fibrosis","volume":"193","author":"Boon","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203161223000_bib23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jcf.2020.06.012","article-title":"Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function","volume":"20","author":"Burgel","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026012203161223000_bib24","doi-asserted-by":"crossref","first-page":"2202029","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"key":"2026012203161223000_bib25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026012203161223000_bib26","doi-asserted-by":"crossref","first-page":"e167957","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"2026012203161223000_bib27","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.30148","article-title":"Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients","volume":"69","author":"Bo\u00eblle","year":"2019","journal-title":"Hepatology"},{"key":"2026012203161223000_bib28","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(11)60004-0","article-title":"European cystic fibrosis bone mineralisation guidelines","volume":"10","author":"Sermet-Gaudelus","year":"2011","journal-title":"J Cyst Fibros"},{"key":"2026012203161223000_bib29","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jcf.2023.08.002","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis","volume":"22","author":"Hergenroeder","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026012203161223000_bib30","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.2337\/dc23-0380","article-title":"Cystic fibrosis-related diabetes workshop: research priorities spanning disease pathophysiology, diagnosis, and outcomes","volume":"46","author":"Putman","year":"2023","journal-title":"Diabetes Care"},{"key":"2026012203161223000_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.03.002","article-title":"Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines","volume":"18","author":"Ramos","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2026012203161223000_bib32","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.healun.2021.07.005","article-title":"Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation","volume":"40","author":"Leard","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"2026012203161223000_bib33","first-page":"100981","article-title":"2022 update of indications and contraindications for lung transplantation in France","volume":"83","author":"Le Pavec","year":"2023","journal-title":"Respir Med Res"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/7\/1053\/66141679\/annalsats_21_7_1053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/7\/1053\/66141679\/annalsats_21_7_1053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:17:23Z","timestamp":1769069843000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/21\/7\/1053\/8405872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202312-1065oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"2023-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}